Open AccessAntibody responses to the BBV152 vaccine in individuals previously infected with SARS-CoV-2: A pilot study
Author(s) -
Nathella Pavan Kumar,
Chandrasekaran Padmapriyadarsini,
Kanchan Devi,
Vaithilingam V. Banurekha,
Arul Nancy,
C. P. Girish Kumar,
Manoj Murhekar,
Nivedita Gupta,
Samiran Panda,
Subash Babu,
Balram Bhargava
Publication year - 2021
Publication title -
indian journal of medical research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.578
H-Index - 87
ISSN - 0971-5916
DOI - 10.4103/ijmr.ijmr_2066_21
Subject(s) - medicine , vaccination , antibody , immunology , immunity , virology , immunoglobulin g , pandemic , cohort , immune system , covid-19 , disease , infectious disease (medical specialty)
Vaccination against SARS-CoV-2 is a recommendation from the World Health Organization as the foremost preference in the current situation to control the COVID-19 pandemic. BBV152 is one of the approved vaccines against SARS-CoV-2 in India. In this study, we determined SARS-CoV-2-specific antibody levels at day 0 (baseline, before vaccination), day 28 ± 2 post-first dose (month 1) and day 56 ± 2 post-first dose (month 2) of BBV152 whole-virion-inactivated SARS-CoV-2 recipients, and compared the antibody responses of individuals with confirmed pre-vaccination SARS-CoV-2 infection to those individuals without prior evidence of infection.